We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information on how to report a serious undesirable effect (SUE) or safeguarding issue for cosmetic products.
Advises on how planning can manage potential noise impacts in new development.
Check what you need to do to sell cosmetic products in Great Britain.
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
Guidance for Marketing Authorisation Holders and holders of other types of authorisations on their responsibilities for veterinary pharmacovigilance and how to report suspected Adverse Events.
Explanation of what Pharmacovigilance means and who is responsible.
Information relating to rare side effects after vaccination.
Forms for the notification of serious undesirable effects (SUEs) from cosmetic products in Great Britain.
Explainer for the pharmaceutical industry on Pharmacovigilance requirements mitigations to bridge the gap between the implementation of the EU Regulation on veterinary medicines and the revised Veterinary Medicines Regulations as they have an effect in Great Britain (GB VMR).
The review of the safety of isotretinoin has concluded.
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
Advises on how to consider light within the planning system.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Guidance relating to blood clotting, myocarditis and Guillain-Barré Syndrome (GBS) after COVID-19 vaccination.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
Details of the Yellow Card scheme, which is the system for recording adverse incidents with medicines and medical devices in the UK.
How to use a cost effectiveness analysis to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.